| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib J Bean, C Brennan, JY Shih, G Riely, A Viale, L Wang, D Chitale, N Motoi, ... Proceedings of the National Academy of Sciences 104 (52), 20932-20937, 2007 | 1988 | 2007 |
| Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up … HW Lo, SC Hsu, W Xia, X Cao, JY Shih, Y Wei, JL Abbruzzese, ... Cancer research 67 (19), 9066-9076, 2007 | 813 | 2007 |
| Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer SG Wu, JY Shih Molecular cancer 17, 1-14, 2018 | 748 | 2018 |
| Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway HW Lo, SC Hsu, M Ali-Seyed, M Gunduz, W Xia, Y Wei, G Bartholomeusz, ... Cancer cell 7 (6), 575-589, 2005 | 650 | 2005 |
| Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non … KY Su, HY Chen, KC Li, ML Kuo, JCH Yang, WK Chan, BC Ho, GC Chang, ... Journal of clinical oncology 30 (4), 433-440, 2012 | 619 | 2012 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 599 | 2019 |
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial JCH Yang, JY Shih, WC Su, TC Hsia, CM Tsai, SHI Ou, CJ Yu, GC Chang, ... The lancet oncology 13 (5), 539-548, 2012 | 523 | 2012 |
| Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer JY Wu, CJ Yu, YC Chang, CH Yang, JY Shih, PC Yang Clinical cancer research 17 (11), 3812-3821, 2011 | 507 | 2011 |
| The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells JL Su, PC Yang, JY Shih, CY Yang, LH Wei, CY Hsieh, CH Chou, ... Cancer cell 9 (3), 209-223, 2006 | 500 | 2006 |
| Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma JL Su, JY Shih, ML Yen, YM Jeng, CC Chang, CY Hsieh, LH Wei, ... Cancer research 64 (2), 554-564, 2004 | 434 | 2004 |
| Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403-1410, 2017 | 373 | 2017 |
| Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response JY Wu, SG Wu, CH Yang, CH Gow, YL Chang, CJ Yu, JY Shih, PC Yang Clinical Cancer Research 14 (15), 4877-4882, 2008 | 367 | 2008 |
| The EMT regulator slug and lung carcinogenesis JY Shih, PC Yang Carcinogenesis 32 (9), 1299-1304, 2011 | 361 | 2011 |
| Identification of a Novel Biomarker, SEMA5A, for Non–Small Cell Lung Carcinoma in Nonsmoking Women TP Lu, MH Tsai, JM Lee, CP Hsu, PC Chen, CW Lin, JY Shih, PC Yang, ... Cancer epidemiology, biomarkers & prevention 19 (10), 2590-2597, 2010 | 322 | 2010 |
| Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non–small-cell lung cancer receiving first-line gefitinib monotherapy CH Yang, CJ Yu, JY Shih, YC Chang, FC Hu, MC Tsai, KY Chen, ZZ Lin, ... Journal of Clinical Oncology 26 (16), 2745-2753, 2008 | 303 | 2008 |
| Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients K Peck, YP Sher, JY Shih, SR Roffler, CW Wu, PC Yang Cancer research 58 (13), 2761-2765, 1998 | 297 | 1998 |
| Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma YL Chang, YC Lee, JY Shih, CT Wu Lung cancer 34 (1), 91-97, 2001 | 290 | 2001 |
| Transcription Repressor Slug Promotes Carcinoma Invasion and Predicts Outcome of Patients with Lung Adenocarcinoma JY Shih, MF Tsai, TH Chang, YL Chang, A Yuan, CJ Yu, SB Lin, GY Liou, ... Clinical cancer research 11 (22), 8070-8078, 2005 | 289 | 2005 |
| The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients SG Wu, YN Liu, MF Tsai, YL Chang, CJ Yu, PC Yang, JCH Yang, YF Wen, ... Oncotarget 7 (11), 12404, 2016 | 266 | 2016 |
| Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations CH Chiu, CT Yang, JY Shih, MS Huang, WC Su, RS Lai, CC Wang, ... Journal of thoracic oncology 10 (5), 793-799, 2015 | 265 | 2015 |
